These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

565 related items for PubMed ID: 29594922

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Relapses of multisystem/multifocal bone Langerhans cell histiocytosis in paediatric patients: Data analysis from the JLSG-96/02 study.
    Sakamoto K, Morimoto A, Shioda Y, Imamura T, Imashuku S, Japan LCH Study Group (JLSG).
    Br J Haematol; 2023 Mar; 200(6):769-775. PubMed ID: 36511451
    [Abstract] [Full Text] [Related]

  • 6. Central diabetes insipidus in pediatric patients with Langerhans cell histiocytosis: Results from the JLSG-96/02 studies.
    Sakamoto K, Morimoto A, Shioda Y, Imamura T, Imashuku S, Japan LCH Study Group (JLSG)Department of Pediatrics, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan..
    Pediatr Blood Cancer; 2019 Jan; 66(1):e27454. PubMed ID: 30207064
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Analysis of 43 cases of Langerhans cell histiocytosis (LCH)-induced central diabetes insipidus registered in the JLSG-96 and JLSG-02 studies in Japan.
    Shioda Y, Adachi S, Imashuku S, Kudo K, Imamura T, Morimoto A.
    Int J Hematol; 2011 Dec; 94(6):545-51. PubMed ID: 22139588
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. [Outcome Comparison of Pediatric Langerhans Cell Histiocytosis Treated with Modified DAL-HX83/90 or JLSG-96 Protocol].
    Huang JB, Jiang L, Chen C, Xue HM.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1190-5. PubMed ID: 27531798
    [Abstract] [Full Text] [Related]

  • 11. Management and Outcome of Patients With Langerhans Cell Histiocytosis and Single-Bone CNS-Risk Lesions: A Multi-Institutional Retrospective Study.
    Chellapandian D, Shaikh F, van den Bos C, Somers GR, Astigarraga I, Jubran R, Degar B, Carret AS, Mandel K, Belletrutti M, Dix D, Visser J, Abuhadra N, Chang T, Rollins B, Whitlock J, Weitzman S, Abla O.
    Pediatr Blood Cancer; 2015 Dec; 62(12):2162-6. PubMed ID: 26179251
    [Abstract] [Full Text] [Related]

  • 12. Intensification of treatment with vinca alkaloid does not improve outcomes in pediatric patients with Langerhans cell histiocytosis: results from the JPLSG LCH-12 study.
    Morimoto A, Shioda Y, Kudo K, Kanegane H, Imamura T, Koh K, Kosaka Y, Yuza Y, Nakazawa A, Saito AM, Watanabe T, Nakazawa Y.
    Int J Hematol; 2023 Jul; 118(1):107-118. PubMed ID: 36871086
    [Abstract] [Full Text] [Related]

  • 13. Craniospinal Langerhans cell histiocytosis in children: 30 years' experience at a single institution.
    Davidson L, McComb JG, Bowen I, Krieger MD.
    J Neurosurg Pediatr; 2008 Mar; 1(3):187-95. PubMed ID: 18352762
    [Abstract] [Full Text] [Related]

  • 14. Clinical and prognostic characteristics of 95 cases of Langerhans cell histiocytosis in children: a single-institute experience from 2013 to 2020.
    Tang X, Gao J, Ma ZG, Guo X, Li Q, Wan Z, Sun JJ.
    Ann Med; 2021 Dec; 53(1):1537-1546. PubMed ID: 34459688
    [Abstract] [Full Text] [Related]

  • 15. Bone lesions of Langerhans cell histiocytosis triggered by trauma in children.
    Morimoto A, Shioda Y, Sakamoto K, Imamura T, Imashuku S, Japan LCH Study Group.
    Pediatr Int; 2022 Jan; 64(1):e15199. PubMed ID: 35770832
    [Abstract] [Full Text] [Related]

  • 16. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group.
    Gadner H, Heitger A, Grois N, Gatterer-Menz I, Ladisch S.
    Med Pediatr Oncol; 1994 Jan; 23(2):72-80. PubMed ID: 8202045
    [Abstract] [Full Text] [Related]

  • 17. Langerhans cell histiocytosis with multifocal bone lesions: comparative clinical features between single and multi-systems.
    Imashuku S, Kinugawa N, Matsuzaki A, Kitoh T, Ohki K, Shioda Y, Tsunematsu Y, Imamura T, Morimoto A, Japan LCH Study Group.
    Int J Hematol; 2009 Nov; 90(4):506-512. PubMed ID: 19779766
    [Abstract] [Full Text] [Related]

  • 18. Langerhans cell histiocytosis: 23 years' paediatric experience highlights severe long-term sequelae.
    Martin A, Macmillan S, Murphy D, Carachi R.
    Scott Med J; 2014 Aug; 59(3):149-57. PubMed ID: 24996784
    [Abstract] [Full Text] [Related]

  • 19. Phase II study in children and adults under 40 years with newly diagnosed Langerhans cell histiocytosis: protocol for an LCH-19-MSMFB clinical trial in Japan.
    Ono R, Sakamoto K, Kudo K, Sato A, Kudo K, Fujino H, Kawahara Y, Hashimoto H, Doi T, Yanagisawa R, Kawamata T, Miyazaki O, Nakazawa A, Ota Y, Kanegane H, Nakazawa Y, Horibe K, Saito AM, Manabe A, Usuki K, Kiyoi H, Morimoto A, Tojo A, Shioda Y.
    BMJ Open; 2024 Jun 23; 14(6):e084159. PubMed ID: 38910000
    [Abstract] [Full Text] [Related]

  • 20. Long-term complications in uniformly treated paediatric Langerhans histiocytosis patients disclosed by 12 years of follow-up of the JLSG-96/02 studies.
    Sakamoto K, Morimoto A, Shioda Y, Imamura T, Imashuku S, Japan LCH Study Group (JLSG).
    Br J Haematol; 2021 Feb 23; 192(3):615-620. PubMed ID: 33236384
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 29.